Pune, Maharashtra -- (SBWIRE) -- 05/11/2017 -- Market Highlights
Conjunctivitis is an eye condition characterized by inflammation of external white part and eyelids. Although this medical condition is caused due to various factors but bacterial and virus are most prominent causes accounting for more than 50% cases of conjunctivitis. The Conjunctivitis Drugs Market is facing stagnant growth in developed regions. Also, a number of patents which have expired such as Moxeza, Besivance, Vigamox, and Zymaxid have dampened the market growth. The market is further characterized by easy entry but high competition which has resulted into greater penetration by generics. The best strategy for firms is market development especially the Asian Pacific market which is poised to lead the growth of the global market in the near future. The market is further dampened by the better efficacy and broad spectrum of anti-bacterial drugs led by quinolones. Quinolones especially Fluoroquinolones has a dominant market share for conjunctivitis. The research pipeline is somewhat weak with many other classes of antibiotics exhibiting greater toxicity. Thus, quinolones have immensely raised the acceptable bar for newer drugs.
The market is chiefly driven by unmet needs in developing regions along with greater awareness and rising incomes in these regions. These reasons along with contagious nature of the disease along with rise of drug resistance also driving the market of other antibiotics which has greater toxicity such as macrolide class. Off label drug use is also one of the market drivers due to cheap generics and greater availability of these drugs.
Major Participants of this Market Are:
- Akorn Pharmaceuticals
- Alcon/ Novartis AG
- Allergan Plc
- Bausch & Lomb
- Valeant Pharmaceuticals
- Merck & Co. Inc.
- Actavis Plc.
- Pfizer Inc.
Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/2513
Global Conjunctivitis Drugs market:
The global conjunctivitis drugs market has been evaluated to be growing and it is expected that it will touch high growth figures in future. The global conjunctivitis drugs market is expected to grow with CAGR of 3.1% in future. Market development and diversification into Asian Pacific market seems to have better strategy for the current situation.
Depending on geographic region, conjunctivitis drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for conjunctivitis drugs followed by Europe. However, the developed regions market is stagnant and any future growth will be led by the developing regions especially Asia pacific region. The unmet drug needs and greater awareness are prime driver of the conjunctivitis drugs market. Greater exposure to allergens and infective agents is also driving the market's growth.
Global conjunctivitis drugs market has been segmented on the basis of conjunctivitis type which comprises of viral, bacterial, allergic and others types of conjunctivitis. On the basis of drug class; market is segmented into antibiotics (quinolones, aminoglycosides, macrolides and others), mast cell stabilizers, steroids and others. On the basis of route of administration; market is segmented into topical, oral and intra-vitreal. On the basis of end users; market is segmented into hospitals and self-administered.
Browse Report @ https://www.marketresearchfuture.com/reports/conjunctivitis-drugs-market-2513
- Conjunctivitis drugs manufacturers
- Conjunctivitis drugs suppliers
- Private research laboratories
- Research and development (R& D) companies
- Market research and consulting service providers
- Government research laboratories
- Contract manufacturing organizations
Global Anesthesia Drugs Market is expected to grow at the average CAGR of 3.7% during 2015-2022. Global Anesthesia Drugs Market is expected to grow US$ 4.9 billion by 2022 from US$ 3.1 billion in 2015. https://www.marketresearchfuture.com/reports/anesthesia-drugs-market-2508
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.